Literature DB >> 11736885

Excretion of low molecular weight heparin in human milk.

C Richter1, J Sitzmann, P Lang, H Weitzel, A Huch, R Huch.   

Abstract

AIMS: The excretion of low molecular weight heparin (LMWH) in breast milk was investigated in 15 lactating mothers after Caesarean section.
METHODS: Blood and milk samples were collected before and 3-4 h after once daily routine subcutaneous injection of 2500 IU dalteparin. Anti-Xa activity was measured by an assay utilizing prolonged clotting times in plasma or breast milk as an index of LMWH activity.
RESULTS: Plasma anti-Xa activities ranged from 0.074 to 0.308 IU ml(-1) of plasma. Anti-Xa activities in breast milk ranged from < 0.005-0.037 IU ml(-1) of milk. This is equivalent to a milk/plasma ratio of < 0.025-0.224.
CONCLUSIONS: Therefore, it appears highly unlikely that puerperal thromboprophylaxis with LMWH has any clinically relevant effect on the nursing infant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736885      PMCID: PMC2014571          DOI: 10.1046/j.0306-5251.2001.01517.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Absence of transplacental passage of fragmin (Kabi) during the second and the third trimesters of pregnancy.

Authors:  F Forestier; Y Solé; M Aiach; M Alhenc Gélas; F Daffos
Journal:  Thromb Haemost       Date:  1992-01-23       Impact factor: 5.249

2.  Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.

Authors:  M Dryjski; D E Schneider; P Mojaverian; B S Kuo; T D Bjornsson
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

3.  Oral heparin results in the appearance of heparin fragments in the plasma of rats.

Authors:  A K Larsen; D P Lund; R Langer; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

4.  The use of low molecular weight heparin for thromboprophylaxis in pregnancy.

Authors:  F Sturridge; M de Swiet; E Letsky
Journal:  Br J Obstet Gynaecol       Date:  1994-01

5.  Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy.

Authors:  A Omri; J F Delaloye; H Andersen; F Bachmann
Journal:  Thromb Haemost       Date:  1989-02-28       Impact factor: 5.249

6.  Use of low molecular weight heparin in pregnancy.

Authors:  E Melissari; C J Parker; N V Wilson; G Monte; C Kanthou; K D Pemberton; K H Nicolaides; J J Barrett; V V Kakkar
Journal:  Thromb Haemost       Date:  1992-12-07       Impact factor: 5.249

7.  [Prevention of thromboembolism with low-molecular weight heparin in pregnancy].

Authors:  J Harenberg; G Leber; R Zimmermann; W Schmidt
Journal:  Geburtshilfe Frauenheilkd       Date:  1987-01       Impact factor: 2.915

8.  Peri- and postnatal, teratology and reproductive studies of a low molecular weight heparin in rats.

Authors:  D Bertoli; G Borelli
Journal:  Arzneimittelforschung       Date:  1986-08
  8 in total
  11 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.

Authors:  Shannon M Bates; Anita Rajasekhar; Saskia Middeldorp; Claire McLintock; Marc A Rodger; Andra H James; Sara R Vazquez; Ian A Greer; John J Riva; Meha Bhatt; Nicole Schwab; Danielle Barrett; Andrea LaHaye; Bram Rochwerg
Journal:  Blood Adv       Date:  2018-11-27

Review 3.  Low-molecular-weight heparins during pregnancy.

Authors:  Ariel Many; Gideon Koren
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

4.  Venous thromboembolism in pregnancy.

Authors:  Marcelo P Villa-Forte Gomes
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

5.  The use of a scoring system to guide thromboprophylaxis in a high-risk pregnant population.

Authors:  D Schoenbeck; A Nicolle; K Newbegin; J Hanley; A D Loughney
Journal:  Thrombosis       Date:  2011-09-08

6.  Guidance for the treatment and prevention of obstetric-associated venous thromboembolism.

Authors:  Shannon M Bates; Saskia Middeldorp; Marc Rodger; Andra H James; Ian Greer
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

Review 7.  Sex matters: Practice 5P's when treating young women with venous thromboembolism.

Authors:  Ingrid M Bistervels; Luuk J J Scheres; Eva N Hamulyák; Saskia Middeldorp
Journal:  J Thromb Haemost       Date:  2019-07-23       Impact factor: 5.824

8.  Post partum female with sudden-onset breathlessness.

Authors:  Kunal Deokar; Ram Niwas; Gopal Chawla; Nishant Chauhan
Journal:  Breathe (Sheff)       Date:  2020-06

9.  Pregnancy and thrombosis risk for women without a history of thrombotic events: a retrospective study of the real risks.

Authors:  Elisavet Grouzi; Abraham Pouliakis; Αnthi Aktypi; Anna Christoforidou; Paraskevi Kotsi; Georgios Αnagnostou; Aikaterini Foifa; Emmanouil Papadakis
Journal:  Thromb J       Date:  2022-10-06

Review 10.  Management of Anticoagulation in Pregnant Women With Mechanical Heart Valves.

Authors:  Molly M Daughety; Jevgenia Zilberman-Rudenko; Joseph J Shatzel; Owen J T McCarty; Vikram Raghunathan; Thomas G DeLoughery
Journal:  Obstet Gynecol Surv       Date:  2020-03       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.